
    
      About 2000 patients with staging I-III of Esophageal Cancer, after accepting chemotherapy,
      will be randomly divided into group A (receive CIK treatment) or group B (just regularly
      follow up), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of
      CIK cells treatment (every 12 weeks). Patients in group B will have no anti-tumor therapy.
    
  